Lupin Ltd has entered into an agreement with Laboratoires Servier, French pharmaceutical company, for the sale of certain patent applications and related Intellectual Property for Perindopril for multiple countries.

Perindopril is used alone or in combination with other medications to treat high blood pressure. "We are really pleased with this agreement with Servier. It goes a long way to demonstrate our Research and IP capabilities," Dr Kamal K Sharma, managing director, Lupin Ltd commented, announcing the deal.

Lupin, which marked its growth in the nine-month period ended December 2006, with the Company's Revenues and Profit after Tax up to Rs 14,985 million (US$ 335 million) and Rs 1,650 million (US$ 37 million) respectively, envisages to leverage from a programme for developing New Chemical Entities.